Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 05 Feb 2026 | Alexandr Hobza Cabinet member | Exchange of views on the structural difficulties of small and medium-sized enterprises (SMEs) in the antibiotics sector in accessing finance to innovate and commercialise, and how EU instruments can better support them. | — |
| 05 Feb 2026 | Alexandr Hobza Cabinet member | Exchange of views on the structural difficulties of small and medium-sized enterprises (SMEs) in the antibiotics sector in accessing finance to innovate and commercialise, and how EU instruments can better support them. | SRC |
| 07 Dec 2022 | Annukka Ojala Cabinet member | Antimicrobial Resistance | — |
| 07 Dec 2022 | Annukka Ojala Cabinet member | Antimicrobial Resistance | SRC |
Mission & Goals
The AMR Action Fund enables breakthroughs in antimicrobials. We invest in companies that are developing urgently needed therapeutics for priority pathogens and advocate for market reforms to change how society values these lifesaving drugs. Our aim is to help launch two to four new antimicrobials in the next decade, and to create a sustainable ecosystem of investment and innovation to take on one of the biggest global health challenges of our generation.
EU Legislative Interests
Activities related to antimicrobial development, including incentives for innovation and equitable access, such as the General Pharmaceutical Legislation Revision and the Critical Medicines Act
Communication Activities
Technical briefing in the European Parliament in April 2025 on antimicrobial resistance. We anticipate further events in 2026, including in the European Parliament.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Member of: Swiss Roundtable on Antibiotics: https://roundtableantibiotics.ch/de/about-us Quadripartite MultiStakeholder Partnership Platform WHO EURO Novel Medicines Platform
Organisation Members
The concept for an investment fund to support companies developing potentially lifesaving antimicrobial therapeutics originated in conversations among the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the World Health Organization, the European Investment Bank, and the Wellcome Trust. Limited Partners (LPs) provide the funding for AMR Action Fund investments: https://www.amractionfund.com/about Investment decisions are taken independently of the LPs, under the authority of the management and decision-making boards of the AMR Action Fund. Many of the LPs (e.g., pharmaceutical companies) are members of trade associations such as IFPMA and EFPIA.